Key Highlights
- Virax Biolabs (NASDAQ:VRAX) was quoted 22.62% higher at USD 1.47 in premarket trading on November 5, 2026.
- Audited cash was USD 6.4 million at March 31, 2026, and the fiscal 2026 net loss narrowed to USD 5.0 million from USD 6.1 million.
- A multi-country Supply agreement with Fosun Diagnostics, announced on July 9, 2026, covers six Southeast Asian markets.
- Nasdaq confirmed on July 13, 2026 that the company regained bid price compliance after a 1-for-25 share consolidation.
Latest Verified Update: Annual Report and Fosun Deal
Virax Biolabs (NASDAQ:VRAX) was quoted at USD 1.47, up 22.62%, in premarket trading on November 5, 2026, per the premarket quote. The most recent verified company update is the Shareholder letter of July 16, 2026, following the annual report filed on July 2, 2026. On July 9, 2026 the company announced a commercial supply agreement with Fosun Diagnostics for its ImmuneSelect research-use-only immune profiling products, covering Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia, initially for tuberculosis-related research in Thailand. Financial terms were not disclosed. Nasdaq confirmed on July 13, 2026 that the company had regained compliance with its minimum bid price rule following a 1-for-25 share consolidation, a mechanism that cuts the share count and raises the quoted price without changing the company's value.
Financial Position and Clinical Plans
For the fiscal year ended March 31, 2026, the audited net loss was USD 5.0 million, down from USD 6.1 million, with Research and Development at USD 3.7 million, up from USD 2.0 million, and general and administrative expenses at USD 2.7 million, down from USD 4.0 million. Cash was USD 6.4 million against total liabilities of USD 1.0 million, and a preferred Investment option exercise completed July 10, 2026 added about USD 3.3 million of gross proceeds. Chief Executive James Foster said Revenue generation remains an area where execution must improve. The company's ViraxImmune T cell platform is in development and is not approved for diagnostic use anywhere; priorities are clinical validation and a United States entry pathway, with no timelines given. The quoted price of USD 1.47 compares with a USD 3.74 close on July 14, 2026, a decline of about 61% (simple arithmetic on two published numbers).
Thin Liquidity and Reversal Risk
Virax is a nano-cap stock. A small number of trades can move the price, spreads can be wide and quoted moves can reverse, so a premarket gain of 22.62% should not be read as the start of a trend. Share consolidations are often followed by further price pressure, and funding through preferred Options and private placements can dilute holders. The company itself has said its market valuation sat below its audited cash and equity, which highlights how little confidence the market has assigned to the pipeline. Investors should watch quarterly cash use, any new financing, evidence of revenue from the Fosun relationship and clinical validation progress for ViraxImmune, as well as Nasdaq listing requirements, which the stock must keep meeting.
Where Things Stand
The 22.62% premarket jump at Virax Biolabs (NASDAQ:VRAX) cannot be tied to a single verified same-day announcement; the latest confirmed items are the Fosun supply agreement, the regained Nasdaq compliance and the annual report, set against audited cash of USD 6.4 million. The balance of evidence is cautious: the loss is narrowing, but revenue is limited and the price is far below its July level. The move is a quote on November 5, 2026 in a very thin stock and can reverse. The next markers are interim financials and any further financing.






Please wait processing your request...